GlassScriptPhysician profile
Valerie Sheppard
NPI 1750524237
$1,222.08
in general payments reported to CMS, 2019-2025
17 companies · $174 in 2025
The $174 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.24 · 2020: $36.53 · 2021: $257 · 2022: $198 · 2023: $252 · 2024: $282 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $708.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $221.52 | 2019-2024 | Bexsero, Rotarix, Pediarix |
| Merck Sharp & Dohme LLC | $216.50 | 2020-2025 | M-M-R II, Vaxneuvance, Gardasil 9 |
| Sanofi Pasteur INC. | $154.19 | 2021-2025 | |
| Corium, LLC | $102.20 | 2023-2024 | Azstarys |
| Pfizer INC. | $78.74 | 2021-2023 | |
| Cognoa, INC. | $75.94 | 2022 | |
| Sanofi-Aventis U.S. LLC | $63.00 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.69 | 2021 | |
| Abbvie INC. | $45.00 | 2021 | |
| Seqirus USA INC | $37.66 | 2023-2024 | Flucelvax, Flucelvax Quadrivalent |
| Supernus Pharmaceuticals, INC. | $34.13 | 2021-2023 | Qelbree |
| Astrazeneca Pharmaceuticals LP | $31.57 | 2024 | Flumist Quadrivalent |
| Ars Pharmaceuticals Operations, INC. | $25.81 | 2025 | Neffy |
| Sobi, INC | $24.42 | 2022 | |
| Tris Pharma INC | $23.91 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $23.05 | 2025 | Neffy |
| Collegium Pharmaceutical, INC. | $18.75 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Valerie Sheppard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.